Biotech Catalysts This Week: FDA Decisions, Readouts & Earnings (Aug 2–Aug 9, 2026)

· 1 min read

Here’s what’s on the biotech calendar for August 2–August 9: 0 FDA decision dates, 2 trial catalysts, and 5 earnings reports from tracked companies.

🧪 Trial Catalysts & Milestones

  • BIIB — 2026-08-06: A Study to Learn About the Safety of BIIB142 and How it is Processed in the Body of Health
  • ARV — 2026-08-08: Testing MK-3475 (Pembrolizumab) After Surgery for Localized Muscle-Invasive Bladder Cancer

📊 Earnings This Week

  • IBRX — 2026-08-03 (est. EPS -0.0714)
  • AXSM — 2026-08-03 (est. EPS -0.7475)
  • ARTV — 2026-08-04 (est. EPS -0.8282)
  • ARVN — 2026-08-04 (est. EPS -0.8459)
  • GILD — 2026-08-05 (est. EPS -7.3679)

📡 Run-up Radar Highlights

Stocks entering the pre-catalyst window with the strongest setups (full radar is a Premium feature):

  • CAPR — BLA in 20 days, score 85/100
  • ACRV — Phase 1 — Recruiting in 10 days, score 53/100
  • CORT — Phase 2 — Active Trial in 30 days, score 45/100

📈 Last Week’s Biggest Gainers

  • HURN +40.37% (volume 5.0x average)
  • FRVO +30.56% (volume 1.2x average)
  • IREN +30.54% (volume 1.5x average)
  • IESC +30.27% (volume 1.9x average)
  • MKTX +29.45% (volume 14.0x average)

Track your tickers on the BioRadar dashboard →

This digest is for informational purposes only and is not investment advice. Always do your own research.

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.